Tagged with research

Belgium Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an innovative specialty pharma player balancing a core business with an increasing focus on specialty areas. He also offers insights on…

UAE Dr Emran Khan, an endocrinologist at King’s College Hospital Dubai, provides an overview of the prevalence of diabetes in the UAE after studies revealed that around 17 percent of the population suffers from the disease. Moreover, Dr Khan analyzes the country’s efforts to combat the disease and the role that…

Belgium Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to the latest EFPIA data. The country has a long-established tradition of excellence in clinical trials and AmCham Belgium estimates that…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

Belgium Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt also delivers a clear message about the importance of continued public and private investments in basic research to foster new…

Czech Republic Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials is decreasing in the Czech Republic, although many continue to capitalize on the country’s universal healthcare system. Vaculík also shares his views on how to retain a strong…

Czech Republic Olga Starobová, medical director of Syneos Health Czech Republic, walks us through the steps put in place to ensure successful synergies during the merger between INC Research and InVentiv Health, which has created a unique company with both clinical and commercial operations under one roof. Starobová talks about her views…

Global With clinical trials having become extremely expensive to conduct, industry buzz around the potential of data and artificial intelligence (AI) to allay these costs has grown. However, experts are split as to the true potential of digital tools to reduce clinical development outlay and provide better patient outcomes in the…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

Belgium Luxembourg Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home to the company’s Heist-op-den-Berg production facility, a key manufacturing site for the global group. Vanneste delivers a strong message about…

Europe EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a world leader in medical innovation.   If the content of the Pharmaceutical Strategy undermines the ambition of the Industrial Strategy then there is a very real, immediate…

Global In an exclusive and wide-ranging interview, Tom O’Leary, chief information officer (CIO) of leading contract research organisation (CRO), ICON, highlights how data is already revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes. O’Leary also…